Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,611 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MDD Clear all
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Bryant, Arkansas • Anaheim, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional Results available

Imaging Biomarkers for TMS Treatment of Depression

NCT01900314
View directory record Official record
Conditions
Depression
Interventions
repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
University of Michigan
Other
Eligibility
22 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 22, 2026, 4:59 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

NCT01128452
View directory record Official record
Conditions
Depression
Interventions
EVT 101, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Oceanside, California • San Diego, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 22, 2026, 4:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Using Voice Biomarkers to Predict the Likelihood of Major Depressive Disorder

NCT04874077
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Kintsugi Mindful Wellness, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
San Francisco, California • Billings, Montana
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Study of Ibuprofen Effects on Brain Function

NCT02507219
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ibuprofen
Drug
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional Results available

Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily Rhythms

NCT05317481
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Mood Disorders, Suicide, Suicidal Ideation
Interventions
BE-SMART-DR, psychoeducational control comparator condition (CC)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
16 Years to 29 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression

NCT01683019
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
NeoSync EEG Synchronization Therapy, Sham NeoSync EEG Synchronization Therapy
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 22, 2026, 4:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sex, Hormones and Gamma-Aminobutyric Acid (GABA) in Stress Induced Anhedonia in Depression

NCT03031665
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 25 Years
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Study to Treat Major Depressive Disorder (MDD) With a New Medication

NCT02149836
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
ezogabine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

The Role Of Omega-3 Fatty Acids In Adolescent Depression

NCT00962598
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Omega 3 Fatty Acids, Corn oil
Drug · Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 19 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional Results available

Vagal Nerve Stimulation for Treatment Resistant Major Depression

NCT04990687
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
gammaCore™
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 22, 2026, 4:59 AM EDT
Withdrawn Phase 2 Interventional

Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder

NCT05652465
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS)
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients

NCT00536471
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
43
States / cities
Beverly Hills, California • Escondido, California • National City, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

PD, PK, and Safety of ALTO-203 in Patients With MDD

NCT06391593
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia
Interventions
ALTO-203 25 μg, ALTO-203 75 μg, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
25 Years to 64 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Tucson, Arizona • Oceanside, California • Torrance, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 3 Interventional

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

NCT00035321
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Olanzapine, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
30
States / cities
Oceanside, California • San Marcos, California • Torrance, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2006 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional

Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation

NCT04502758
View directory record Official record
Conditions
Suicidal Ideation, Major Depressive Disorder
Interventions
MagVenture TMS Therapy System w/Theta Burst Stimulation, Sham MagVenture TMS Therapy System w/Theta Burst Stimulation
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Recruiting Phase 3 Interventional

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

NCT07573176
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
34
States / cities
Bryant, Arkansas • Bellflower, California • Glendale, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 4 Interventional Results available

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00404755
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia
Interventions
escitalopram, bupropion, imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Get Moving and Get Well - Pilot Study

NCT01884025
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression, Post Traumatic Stress Disorder
Interventions
Get Moving and Get Well, Health and Humor Class
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
North Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 22, 2026, 4:59 AM EDT
Terminated Phase 4 Interventional Results available

Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine

NCT02969876
View directory record Official record
Conditions
Depressive Disorder, Major Depression, Depression, Depression, Unipolar
Interventions
Vortioxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 22, 2026, 4:59 AM EDT
Recruiting Not applicable Interventional

Using TMS to Understand Neural Processes of Social Motivation

NCT06274112
View directory record Official record
Conditions
Social Avoidant Behavior, Major Depressive Disorder, Social Anxiety Disorder
Interventions
TMS
Device
Lead sponsor
Auburn University
Other
Eligibility
25 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional

Study to Assess the Safety and Effectiveness of NMRA-335140-501

NCT06029439
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NMRA-335140
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
904 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
126
States / cities
Huntsville, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 22, 2026, 4:59 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT07196501
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NBI-1065845, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Oceanside, California • Orange, California • San Jose, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 4:59 AM EDT